TY - JOUR
T1 - Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies
T2 - Results from the international Sickle Cell World Assessment Survey (SWAY)
AU - Osunkwo, Ifeyinwa
AU - Andemariam, Biree
AU - Minniti, Caterina P.
AU - Inusa, Baba P.D.
AU - El Rassi, Fuad
AU - Francis-Gibson, Beverley
AU - Nero, Alecia
AU - Trimnell, Cassandra
AU - Abboud, Miguel R.
AU - Arlet, Jean Benoît
AU - Colombatti, Raffaella
AU - de Montalembert, Mariane
AU - Jain, Suman
AU - Jastaniah, Wasil
AU - Nur, Erfan
AU - Pita, Marimilia
AU - DeBonnett, Laurie
AU - Ramscar, Nicholas
AU - Bailey, Tom
AU - Rajkovic-Hooley, Olivera
AU - James, John
N1 - Publisher Copyright:
© 2020 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Sickle cell disease (SCD) is a genetic disorder, characterized by hemolytic anemia and vaso-occlusive crises (VOCs). Data on the global SCD impact on quality of life (QoL) from the patient viewpoint are limited. The international Sickle Cell World Assessment Survey (SWAY) aimed to provide insights into patient-reported impact of SCD on QoL. This cross-sectional survey of SCD patients enrolled by healthcare professionals and advocacy groups assessed disease impact on daily life, education and work, symptoms, treatment goals, and disease management. Opinions were captured using a Likert scale of 1-7 for some questions; 5-7 indicated “high severity/impact.” Two thousand one hundred and forty five patients (mean age 24.7 years [standard deviation (SD) = 13.1], 39% ≤18 years, 52% female) were surveyed from 16 countries (six geographical regions). A substantial proportion of patients reported that SCD caused a high negative impact on emotions (60%) and school achievement (51%) and a reduction in work hours (53%). A mean of 5.3 VOCs (SD = 6.8) was reported over the 12 months prior to survey (median 3.0 [interquartile range 2.0-6.0]); 24% were managed at home and 76% required healthcare services. Other than VOCs, fatigue was the most commonly reported symptom in the month before survey (65%), graded “high severity” by 67% of patients. Depression and anxiety were reported by 39% and 38% of patients, respectively. The most common patient treatment goal was improving QoL (55%). Findings from SWAY reaffirm that SCD confers a significant burden on patients, epitomized by the high impact on patientsʼ QoL and emotional wellbeing, and the high prevalence of self-reported VOCs and other symptoms.
AB - Sickle cell disease (SCD) is a genetic disorder, characterized by hemolytic anemia and vaso-occlusive crises (VOCs). Data on the global SCD impact on quality of life (QoL) from the patient viewpoint are limited. The international Sickle Cell World Assessment Survey (SWAY) aimed to provide insights into patient-reported impact of SCD on QoL. This cross-sectional survey of SCD patients enrolled by healthcare professionals and advocacy groups assessed disease impact on daily life, education and work, symptoms, treatment goals, and disease management. Opinions were captured using a Likert scale of 1-7 for some questions; 5-7 indicated “high severity/impact.” Two thousand one hundred and forty five patients (mean age 24.7 years [standard deviation (SD) = 13.1], 39% ≤18 years, 52% female) were surveyed from 16 countries (six geographical regions). A substantial proportion of patients reported that SCD caused a high negative impact on emotions (60%) and school achievement (51%) and a reduction in work hours (53%). A mean of 5.3 VOCs (SD = 6.8) was reported over the 12 months prior to survey (median 3.0 [interquartile range 2.0-6.0]); 24% were managed at home and 76% required healthcare services. Other than VOCs, fatigue was the most commonly reported symptom in the month before survey (65%), graded “high severity” by 67% of patients. Depression and anxiety were reported by 39% and 38% of patients, respectively. The most common patient treatment goal was improving QoL (55%). Findings from SWAY reaffirm that SCD confers a significant burden on patients, epitomized by the high impact on patientsʼ QoL and emotional wellbeing, and the high prevalence of self-reported VOCs and other symptoms.
UR - http://www.scopus.com/inward/record.url?scp=85099756043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099756043&partnerID=8YFLogxK
U2 - 10.1002/ajh.26063
DO - 10.1002/ajh.26063
M3 - Article
C2 - 33264445
AN - SCOPUS:85099756043
SN - 0361-8609
VL - 96
SP - 404
EP - 417
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 4
ER -